Premium
Functional analyses of STIM1 mutations reveal a common pathomechanism for tubular aggregate myopathy and Stormorken syndrome
Author(s) -
Peche Georges Arielle,
Spiegelhalter Coralie,
SilvaRojas Roberto,
Laporte Jocelyn,
Böhm Johann
Publication year - 2020
Publication title -
neuropathology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.701
H-Index - 61
eISSN - 1440-1789
pISSN - 0919-6544
DOI - 10.1111/neup.12692
Subject(s) - myopathy , orai1 , nfat , microbiology and biotechnology , stim1 , biology , mutation , medicine , endocrinology , transcription factor , genetics , cancer research , gene , endoplasmic reticulum
Tubular aggregate myopathy (TAM) is a progressive disorder characterized by muscle weakness, cramps, and myalgia. TAM clinically overlaps with Stormorken syndrome (STRMK), combining TAM with miosis, thrombocytopenia, hyposplenism, ichthyosis, short stature, and dyslexia. TAM and STRMK arise from gain‐of‐function mutations in STIM1 (stromal interaction molecule 1) or ORAI1 , both encoding key regulators of Ca 2+ homeostasis, and mutations in either gene result in excessive extracellular Ca 2+ entry. The pathomechanistic similarities and differences between TAM and STRMK are only partially understood. Here we provide functional in vitro experiments demonstrating that STIM1 harboring the TAM D84G or the STRMK R304W mutation similarly cluster and exert a dominant effect on the wild‐type protein. Both mutants recruit ORAI1 to the clusters, increase cytosolic Ca 2+ levels, promote major nuclear import of the Ca 2+ ‐dependent transcription factor NFAT (nuclear factor of activated T cells), and trigger the formation of circular membrane stacks. In conclusion, the analyzed TAM and STRMK mutations have a comparable impact on STIM1 protein function and downstream effects of excessive Ca 2+ entry, highlighting that TAM and STRMK involve a common pathomechanism.